William J Murphy

List of Publications by Year
in descending order

156 papers	8,363 citations	44069 48 h-index	53230 85 g-index
157 all docs	157 docs citations	157 times ranked	11387 citing authors

#	Article	IF	Citations
1	Advances in graft-versus-host disease biology and therapy. Nature Reviews Immunology, 2012, 12, 443-458.	22.7	746
2	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nature Medicine, 2019, 25, 141-151.	30.7	539
3	Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation. Annual Review of Immunology, 2007, 25, 139-170.	21.8	454
4	'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nature Immunology, 2010, 11, 321-327.	14.5	239
5	Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8120-8125.	7.1	238
6	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood, 2012, 119, 1570-1580.	1.4	221
7	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood, 2014, 123, 3988-3998.	1.4	179
8	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. Journal of Clinical Investigation, 2014, 124, 4867-4876.	8.2	173
9	NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. Journal of Immunology, 2015, 195, 4010-4019.	0.8	173
10	IFN-Î³ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nature Medicine, 2007, 13, 354-360.	30.7	163
11	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood, 2016, 127, 2144-2154.	1.4	145
12	Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood, 2001, 97, 3132-3137.	1.4	139
13	Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition. Journal of Immunology, 2008, 180, 163-170.	0.8	138
14	Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. Journal of Experimental Medicine, 2013, 210, 2223-2237.	8.5	132
15	Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5460-5465.	7.1	131
16	Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. Journal of Experimental Medicine, 2014, 211, 2373-2383.	8.5	124
17	Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. Frontiers in Cellular and Infection Microbiology, 2020, 10, 49.	3.9	122
18	Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood, 2005, 106, 3293-3299.	1.4	110

#	Article	IF	Citations
19	Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses. Journal of Immunology, 2003, 170, 2727-2733.	0.8	105
20	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood, 2015, 126, 1621-1628.	1.4	104
21	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood, 2015, 125, 4085-4094.	1.4	101
22	Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. , 2017, 5, 98.		101
23	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood, 2016, 128, 1013-1017.	1.4	95
24	Western Dietâ€“Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment. American Journal of Pathology, 2017, 187, 1800-1813.	3.8	90
25	Minimal PD-1 expression in mouse and human NK cells under diverse conditions. Journal of Clinical Investigation, 2020, 130, 3051-3068.	8.2	90
26	Therapeutic Efficacy of Fresh, Autologous Mesenchymal Stem Cells for Severe Refractory Gingivostomatitis in Cats. Stem Cells Translational Medicine, 2016, 5, 75-86.	3.3	88
27	Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies. Biology of Blood and Marrow Transplantation, 2015, 21, 24-29.	2.0	87
28	Canine cancer immunotherapy studies: linking mouse and human. , 2016, 4, 97.		86
29	Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity. Immunity, 2015, 43, 240-250.	14.3	83
30	Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. JCI Insight, 2017, 2, e90521.	5.0	83
31	Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nature Communications, 2020, 11, 4591.	12.8	81
32	Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nature Reviews Clinical Oncology, 2020, 17, 475-492.	27.6	80
33	Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunology, Immunotherapy, 2014, 63, 21-28.	4.2	78
34	Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19455-19460.	7.1	77
35	Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nature Communications, 2022, 13, 1511.	12.8	77
36	Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy. Blood, 2012, 119, 3073-3083.	1.4	76

#	Article	IF	Citations
37	Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy. Expert Opinion on Biological Therapy, 2017, 17, 313-324.	3.1	75
38	Therapeutic Efficacy of Fresh, Allogeneic Mesenchymal Stem Cells for Severe Refractory Feline Chronic Gingivostomatitis. Stem Cells Translational Medicine, 2017, 6, 1710-1722.	3.3	74
39	Treatment of chronic graft-versus-host disease with bortezomib. Blood, 2014, 124, 1677-1688.	1.4	72
40	A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination. New England Journal of Medicine, 2022, 386, 394-396.	27.0	70
41	The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy. JAMA - Journal of the American Medical Association, 2019, 321, 1247.	7.4	69
42	Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. OncoImmunology, 2015, 4, e1036212.	4.6	64
43	The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. European Journal of Cancer, 2017, 75, 268-279.	2.8	62
44	Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/Î±CD40 Therapy. Journal of Immunology, 2014, 192, 5821-5829.	0.8	60
45	NK Cellsâ€"From Bench to Clinic. Biology of Blood and Marrow Transplantation, 2012, 18, S2-S7.	2.0	58
46	Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. Theranostics, 2018, 8, 3611-3628.	10.0	58
47	Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. JCI Insight, 2019, 4, .	5.0	57
48	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood, 2015, 125, 3335-3346.	1.4	55
49	Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. , 2020, 8, e001355.		55
50	Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1259-1270.	0.8	54
51	The immunobiology of natural killer cells and bone marrow allograft rejection. Biology of Blood and Marrow Transplantation, 2003, 9, 727-741.	2.0	53
52	Obesity induced T cell dysfunction and implications for cancer immunotherapy. Current Opinion in Immunology, 2018, 51, 181-186.	5.5	52
53	Positive and Negative Regulation by NK Cells in Cancer. Critical Reviews in Oncogenesis, 2014, 19, 57-66.	0.4	52
54	Influenza infection results in local expansion of memory CD8+ T cells with antigen non-specific phenotype and function. Clinical and Experimental Immunology, 2013, 175, 79-91.	2.6	51

#	Article	IF	Citations
55	Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood, 2013, 122, 2125-2134.	1.4	47
56	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. OncoImmunology, 2016, 5, e1075114.	4.6	47
57	Mouse NK cellâ€“mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood, 2012, 119, 1590-1598.	1.4	45
58	Positive and negative regulation of Natural Killer cells: Therapeutic implications. Seminars in Cancer Biology, 2006, 16, 367-382.	9.6	44
59	Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. Blood, 2011, 117, 7032-7041.	1.4	44
60	Stimulating Innate Immunity to Enhance Radiation Therapyâ€“Induced Tumor Control. International Journal of Radiation Oncology Biology Physics, 2017, 99, 362-373.	0.8	43
61	Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. , 2017, 5, 33.		43
62	Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cellâ€“Mediated Antitumor Responses. Biology of Blood and Marrow Transplantation, 2008, 14, 1088-1099.	2.0	42
63	Human and feline adipose-derived mesenchymal stem cells have comparable phenotype, immunomodulatory functions, and transcriptome. Stem Cell Research and Therapy, 2017, 8, 69.	5.5	42
64	Natural killer cell immunotherapy to target stem-like tumor cells. , 2016, 4, 19.		41
65	Increased Antitumor Effects Using IL-2 with Antiâ€“TGF-Î² Reveals Competition between Mouse NK and CD8 T Cells. Journal of Immunology, 2014, 193, 1709-1716.	0.8	39
66	Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7401-7406.	7.1	38
67	Immunoediting and Antigen Loss: Overcoming the Achilles Heel of Immunotherapy with Antigen Non-Specific Therapies. Frontiers in Oncology, 2013, 3, 197.	2.8	36
68	The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. Journal of Immunotoxicology, 2012, 9, 248-258.	1.7	34
69	High fluence light emitting diodeâ€generated red light modulates characteristics associated with skin fibrosis. Journal of Biophotonics, 2016, 9, 1167-1179.	2.3	33
70	Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Veterinary and Comparative Oncology, 2019, 17, 49-60.	1.8	33
71	Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood, 2008, 112, 1522-1529.	1.4	31
72	Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Developmental and Comparative Immunology, 2018, 87, 64-74.	2.3	31

#	Article	IF	Citations
73	Licensing delineates helper and effector NK cell subsets during viral infection. JCI Insight, 2017, 2, .	5.0	30
74	Mechanical Disruption of Tumors by Iron Particles and Magnetic Field Application Results in Increased Anti-Tumor Immune Responses. PLoS ONE, 2012, 7, e48049.	2.5	29
75	Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantation. Science Translational Medicine, 2020, 12, .	12.4	29
76	Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features. Journal of the American Academy of Dermatology, 2018, 79, 221-229.	1.2	28
77	Bystander Activation and Anti-Tumor Effects of CD8+ T Cells Following Interleukin-2 Based Immunotherapy Is Independent of CD4+ T Cell Help. PLoS ONE, 2014, 9, e102709.	2.5	26
78	Reprint of: Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies. Biology of Blood and Marrow Transplantation, 2015, 21, S19-S24.	2.0	26
79	CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. Journal of Controlled Release, 2015, 220, 253-264.	9.9	26
80	Leveraging natural killer cells for cancer immunotherapy. Immunotherapy, 2017, 9, 487-497.	2.0	26
81	Obesity as an immune-modifying factor in cancer immunotherapy. Journal of Leukocyte Biology, 2018, 104, 487-497.	3.3	25
82	Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels. Biology of Blood and Marrow Transplantation, 2014, 20, 1899-1904.	2.0	24
83	Models to Study NK Cell Biology and Possible Clinical Application. Current Protocols in Immunology, 2015, 110, 14.37.1-14.37.14.	3.6	24
84	Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer, 2014, 14, 756.	2.6	23
85	Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. Blood, 2013, 122, 1518-1521.	1.4	22
86	Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy. Journal of Immunology, 2008, 180, 2981-2988.	0.8	21
87	Natural Killer Cell Subsets Differentially Reject Embryonic Stem Cells Based on Licensing. Transplantation, 2014, 97, 992-998.	1.0	21
88	Impact of aging in cancer immunotherapy. OncoImmunology, 2013, 2, e27186.	4.6	20
89	Obesity and cancer immunotherapy toxicity. Immunotherapy, 2015, 7, 319-322.	2.0	20
90	Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. Journal of Surgical Research, 2018, 223, 207-214.	1.6	20

#	Article	IF	Citations
91	Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment. Blood, 2016, 127, 1202-1205.	1.4	19
92	Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells. Cancers, 2019, 11, 85.	3.7	18
93	Preclinical modeling of hematopoietic stem cell transplantation â€“ advantages and limitations. FEBS Journal, 2016, 283, 1595-1606.	4.7	17
94	Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma. Veterinary and Comparative Oncology, 2019, 17, 242-252.	1.8	15
95	Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS ONE, 2020, 15, e0224775.	2.5	15
96	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. , 2021, 9, e002627.		15
97	Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2b bone marrow cell allografts. Blood, 2000, 95, 3840-3844.	1.4	14
98	IFN-Î³ Receptor-Deficient Donor T Cells Mediate Protection from Graft-versus-Host Disease and Preserve Graft-versus-Tumor Responses after Allogeneic Bone Marrow Transplantation. Journal of Immunology, 2012, 189, 2033-2042.	0.8	13
99	Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1754-1764.	2.0	12
100	Immune targeting of cancer stem cells in gastrointestinal oncology. Journal of Gastrointestinal Oncology, 2016, 7, S1-S10.	1.4	12
101	Antibodies to CD40 Promote Dendritic Cell Recovery and Anti-Tumor Effects after Syngeneic Bone Marrow Transplant (BMT).. Blood, 2005, 106, 1305-1305.	1.4	12
102	Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target. Frontiers in Immunology, 2021, 12, 670309.	4.8	11
103	Resveratrol Prevents High Fluence Red Light-Emitting Diode Reactive Oxygen Species-Mediated Photoinhibition of Human Skin Fibroblast Migration. PLoS ONE, 2015, 10, e0140628.	2.5	11
104	Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice. Biology of Blood and Marrow Transplantation, 2017, 23, 30-37.	2.0	10
105	Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. Journal of Immunology, 2019, 202, 2795-2805.	0.8	10
106	The complicated effects ofÂ obesity on cancer and immunotherapy. Immunotherapy, 2019, 11, 11-14.	2.0	10
107	Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response. , 2022, 10, e004493.		10
108	Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. Cancer Immunology, Immunotherapy, 2015, 64, 1541-1552.	4.2	9

#	Article	IF	Citations
109	Targeting PI3KÎ´ function for amelioration of murine chronic graft-versus-host disease. American Journal of Transplantation, 2019, 19, 1820-1830.	4.7	9
110	PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment. Frontiers in Immunology, 2020, 11, 590568.	4.8	9
111	Mechanisms by Which Obesity Promotes Acute Graft-Versus-Host Disease in Mice. Frontiers in Immunology, 2021, 12, 752484.	4.8	9
112	IL-2 and Anti-TGF-Î² Promote NK Cell Reconstitution and Anti-tumor Effects after Syngeneic Hematopoietic Stem Cell Transplantation. Cancers, 2020, 12, 3189.	3.7	8
113	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood, 2021, 137, 1090-1103.	1.4	8
114	Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects. Blood, 2021, 138, 2583-2588.	1.4	8
115	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. JCI Insight, 2019, 4, .	5.0	8
116	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
117	A possible new pathway in natural killer cell activation also reveals the difficulty in determining human NK cell function in cancer. , 2018, 6, 79.		7
118	Organ-Specific Protection from CD8+ T Cell-Mediated Acute Skin GVHD by Bortezomib Administration Correlates with Decreased IL-6.. Blood, 2010, 116, 3735-3735.	1.4	7
119	Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?. International Reviews of Immunology, 2011, 30, 238-293.	3.3	5
120	Autoimmune T Cells Lured to a FASL Web of Death by MSCs. Cell Stem Cell, 2012, 10, 485-487.	11.1	5
121	Being â€œpenny-wise but pound foolishâ€•in cancer immunotherapy research: the urgent need for mouse cancer models to reflect human modifying factors. , 2016, 4, 88.		5
122	Natural Killer Cells in GvHD and GvL. , 2019, , 275-292.		5
123	Attenuated Age-Impact on Systemic Inflammatory Markers in the Presence of a Metabolic Burden. PLoS ONE, 2015, 10, e0121947.	2.5	5
124	Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. , 2019, 7, 291.		4
125	The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation. Gut Microbes, 2021, 13, 1966262.	9.8	4
126	Blood Stem Cell Transplantation in Older Patients. Biology of Blood and Marrow Transplantation, 2009, 15, 1638-1639.	2.0	3

#	Article	IF	Citations
127	Donor HSCs with a preexisting ASXL1-mutation led to the development of FLT3-ITD positive AML in the donor and FLT3-ITD negative AML in the recipient after unrelated transplant. Bone Marrow Transplantation, 2018, 53, 499-502.	2.4	3
128	Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. Cancers, 2021, 13, 729.	3.7	3
129	Re-Examining the Paradigm of Impaired Healing in the Aged Murine Excision Wound Model. Journal of Investigative Dermatology, 2021, 141, 1071-1075.e4.	0.7	3
130	NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms. , 2021, , 3-31.		2
131	The urgent need for more basic research on SARS-Cov2 infection and vaccines in assessing potential psychoneurological effects using maternal immune activation (MIA) and other preclinical modeling. Brain, Behavior, and Immunity, 2021, 97, 1-3.	4.1	2
132	ASXL1-Mutated Donor HSCs Evolved into FLT3-ITD Positive AML in the Unrelated Donor and FLT3-ITD Negative AML in the Recipient after Transplant. Blood, 2015, 126, 5403-5403.	1.4	2
133	Immunoregulatory pathways following strong inflammatory processes markedly impair CD4+ T cell responses. Human Vaccines and Immunotherapeutics, 2016, 12, 2249-2252.	3.3	1
134	Making a Better Hematopoietic Stem Cell â€" Timing Is Everything. New England Journal of Medicine, 2018, 378, 89-91.	27.0	1
135	Skin-Resident Î²2AR Signaling Delays Burn Wound Healing. Journal of Investigative Dermatology, 2021, 141, 2098-2101.e4.	0.7	1
136	Activation Status Dictates the Function of Unlicensed Natural Killer Cells. Blood Advances, 2021, 5, 4219-4232.	5.2	1
137	Natural Killer (NK) Cell Recovery After Bone Marrow Transplantation in Mice: Early Emergence of a Novel Ly49+ Stage in Differentiation Independent of MHC Haplotype.. Blood, 2009, 114, 4477-4477.	1.4	1
138	Natural Killer Cell Licensing Delineates NK â€œHelper/Repairâ€•and NK â€œEffector/Suppressorâ€•Subsets During Viral Infections. Blood, 2013, 122, 13-13.	1.4	1
139	Immunomodulatory Effects of the Triterpenoid CDDO after Allogeneic Bone Marrow Transplantation in Mice: Reduction of Acute Graft-Versus-Host Disease Lethality.. Blood, 2005, 106, 1316-1316.	1.4	0
140	Suppression of NK Cell-Mediated Bone Marrow Cell Rejection by CD4+CD25+ Regulatory T Cells: Linkage of Adaptive to Innate Responses.. Blood, 2005, 106, 2195-2195.	1.4	0
141	Removal of Donor CD4+ T Cells Markedly Promotes Graft-Versus-Tumor (GVT) Effects and Inhibits GVHD-Dependent Toxicity Associated with Prolonged Bortezomib Administration after Allogeneic BMT.. Blood, 2006, 108, 3160-3160.	1.4	0
142	In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs.. Blood, 2006, 108, 446-446.	1.4	0
143	Dissociating GVT from GVHD in Murine BMT Models through TNFÎ± Dependent CD4+ T Cell Mediated GVHD and IFNÎ³ Dependent CD8+ T Cell Mediated Anti-Tumor Effects.. Blood, 2007, 110, 69-69.	1.4	0
144	CD4+CD25+Foxp3+ Regulatory T Cell Function Outside the Immune System: Differential Regulation of Hematopoietic Progenitor Cell Populations.. Blood, 2007, 110, 64-64.	1.4	0

#	Article	IF	Citations
145	The Antioxidant Inflammation Modulator, CDDO-Me Promotes Myelopoiesis in Mice.. Blood, 2008, 112, 2335-2335.	1.4	0
146	NK Cell-Mediated Rejection of Bone Marrow Cells- In Vivo Evidence of NK Cell Subset Licensing.. Blood, 2009, 114, 3537-3537.	1.4	0
147	Organ-Specific Protection By Bortezomib On The Treatment Of Cutaneous Chronic and Acute GvHD. Blood, 2013, 122, 4473-4473.	1.4	0
148	Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model. Blood, 2013, 122, 292-292.	1.4	0
149	Evidence That Novel NK-NK Cell Subset Regulation Exists With Regard To Effects In Tumor and Viral Models. Blood, 2013, 122, 1038-1038.	1.4	0
150	Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality. Blood, 2015, 126, 147-147.	1.4	0
151	Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 1922-1922.	1.4	0
152	AML Cell Vaccines Co-Expressing CD80 and IL-15/IL-15 Receptor Alpha Induce Activation and Cytolytic Activity in Post Remission Autologous Patient PBMC Ex Vivo. Blood, 2021, 138, 1706-1706.	1.4	0
153	Title is missing!. , 2020, 15, e0224775.		0
154	Title is missing!. , 2020, 15, e0224775.		0
155	Title is missing!. , 2020, 15, e0224775.		0
156	Title is missing!. , 2020, 15, e0224775.		0